Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticles

Drug Development and Industrial Pharmacy

Volumn 41, Issue 5, 2015, Pages 764-771

  Bu, Xiangyuan ^a   Zhu, Tao ^a   Ma, Yiran ^a   Shen, Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bioavailability; Cell penetrating peptide; Cyclodextrin inclusion; Docetaxel; Nanoparticles; PLGA

Indexed keywords

ARGININE DERIVATIVE; CELL PENETRATING PEPTIDE; CYCLODEXTRIN; DOCETAXEL; LACTATE DEHYDROGENASE; NANOPARTICLE; POLYGLACTIN; TRITON X 100; ANTINEOPLASTIC AGENT; DRUG CARRIER; EMULSION; HEPTAARGININE AMIDE; LACTIC ACID; OLIGOPEPTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TAXOID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; CELL MEMBRANE; CELL VIABILITY; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; EMULSION; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MCF 7 CELL LINE; MEAN RESIDENCE TIME; MTT ASSAY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SCANNING ELECTRON MICROSCOPE; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG RELEASE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; EMULSIONS; HUMANS; LACTIC ACID; MALE; MCF-7 CELLS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OLIGOPEPTIDES; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS;

EID: 84930363941     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.902465     Document Type: Article

References (37)

1. Bissery MC. Preclinical pharmacology of docetaxel. Eur J Cancer 1995;31:S1-6.
2. Lavelle F, Bissery MC, Combeau C. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22:3-16.
3. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
4. Hill BT, Whelan RD, Shellard SA, et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drug 1994;12: 169-82.
5. Nassar T, Attili-Qadri S, Harush-Frenkel O, et al. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res 2011;71: 3018-28.
6. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62: 6158-64.
7. Horwitz S. Mechanism of action of taxol. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Trends Pharmacol Sci 1992;13:134-6.
8. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85.
9. Musumeci T, Ventura CA, Giannone I, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006; 325:172-9.
10. Liu DH, Liu ZH, Wang LL, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011;85:262-9.
11. Xu ZH, Chen LL, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009;30:226-32.
12. Dong Y, Feng SS. Poly(d, l-lactide-co-glycolide) (PLGA) nanopar-ticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm 2007;342:208-14.
13. Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm 2012;81:265-72.
14. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci 2008;97:3518-90.
15. Vert M, Mauduit J, Li S. Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials 1994;15:1209-13.
16. Sharma A, Straubinger RM. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res 1994;11:889-95.
17. Sharma US, Balasubramanian SV, Straubinger RM. Pharmaceutical and physical properties of Paclitaxel (taxol) complexes with cyclodextrins. J Pharm Sci 1995;84:781-91.
18. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 2011;1816:232-46.
19. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005;62:1839-49.
20. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009;61:953-64.
21. Chen Y, Yuan L, Zhou L, et al. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomedicine 2012;7:4581-91.
22. Zhang Z, Lv H, Zhou J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Pharmazie 2009;64:574-8.
23. Noriyasu K, Mariko M, Yoshimi E, et al. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 2008;132:21-5.
24. El-Sayed K, Mariko M, Noriyasu K, et al. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int J Pharm 2009;381:49-55.
25. Wu J, Shen Q, Fang L. Sulfobutylether-b-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel. Drug Dev Ind Pharm 2013;39:1010-19.
26. Wu DQ, Lu B, Chang C, et al. Galactosylated fluorescent labeled micelles as a liver targeting drug carrier. Biomaterials 2009;30: 1363-71.
27. Luo Y, Ling Y, Guo W, et al. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apop-tosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release 2010;147:278-88.
28. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparti-cles affects their physical properties and cellular uptake. J Control Release 2002;82:105-14.
29. Damge C, Aprahamian M, Marchais H, et al. Intestinal absorption of PLAGA microspheres in the rat. J Anat 1996;189: 491-501.
30. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 2005;57:637-51.
31. Marty C, Meylan C, Schott H, et al. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol Life Sci 2004;61:1785-94.
32. Mitchell DJ, Kim DT, Steinman L, et al. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000;56:318-25.
33. Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-90.
34. Kamei N, Morishita M, Eda Y, et al. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 2008;132:21-5.
35. Hirose H, Takeuchi T, Osakada H, et al. Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol Ther 2012;20:984-93.
36. Liang CY, Yang YB, Ling Y, Huang YS. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorg Med Chem 2011;19:4057-66.
37. Wang H, Zhao Y, Wu Y, Hu YL. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011; 32:8281-90.